Anti-CD19 chimeric antigen receptor T cell therapy- BiocurePharm
Alternative Names: Anti-CD19 CAR-T cell therapy - BiocurePharmLatest Information Update: 28 Nov 2022
At a glance
- Originator BiocurePharm
- Developer BiocurePharm; Pharos Vaccine
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for preclinical development in Precursor-cell-lymphoblastic-leukaemia-lymphoma in South Korea (IV, Injection)
- 23 Jan 2019 BiocurePharm announces intention to launch anti-CD19 CAR-T cell therapy for Precursor cell lymphoblastic leukaemia-lymphoma in 2020
- 23 Jan 2019 BiocurePharm plans clinical trials for Precursor cell lymphoblastic leukaemia-lymphoma in 2019